Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Merkel cell carcinoma has historically had dismal prognosis with limited cytotoxic chemotherapy options that provide durable control of metastatic disease. The advent of anti-programmed death protein (anti-PD1)/anti-programmed death-ligand 1 (anti-PD-L1) directed immunotherapy has shown initial prom...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Bloom, Brooke C., Augustyn, Alexander, Pezzi, Todd A., Menon, Hari, Mayo, Lauren L., Shah, Shalin J., Schwartz, David L., Chmura, Steven J., Johnson, Faye M., Welsh, James W., Chun, Stephen G.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2019
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459944/
https://ncbi.nlm.nih.gov/pubmed/31024834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00223
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires